Emergent variant modeling of the serological repertoire to norovirus in young children.
antigenic cartography
antigenic seniority
blockade antibodies
immune imprinting
neutralizing antibodies
norovirus
variants of concern
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
21 03 2023
21 03 2023
Historique:
received:
14
09
2022
revised:
05
12
2022
accepted:
02
02
2023
pubmed:
1
3
2023
medline:
25
3
2023
entrez:
28
2
2023
Statut:
ppublish
Résumé
Human norovirus is the leading cause of acute gastroenteritis. Young children and the elderly bear the greatest burden of disease, representing more than 200,000 deaths annually. Infection prevalence peaks at younger than 2 years and is driven by novel GII.4 variants that emerge and spread globally. Using a surrogate neutralization assay, we characterize the evolution of the serological neutralizing antibody (nAb) landscape in young children as they transition between sequential GII.4 pandemic variants. Following upsurge of the replacement variant, antigenic cartography illustrates remodeling of the nAb landscape to the new variant accompanied by improved nAb titer. However, nAb relative avidity remains focused on the preceding variant. These data support immune imprinting as a mechanism of immune evasion and GII.4 virus persistence across a population. Understanding the complexities of immunity to rapidly evolving and co-circulating viral variants, like those of norovirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), and dengue viruses, will fundamentally inform vaccine design for emerging pathogens.
Identifiants
pubmed: 36854303
pii: S2666-3791(23)00046-0
doi: 10.1016/j.xcrm.2023.100954
pmc: PMC10040388
pii:
doi:
Substances chimiques
Antibodies, Viral
0
RNA, Viral
0
Epitopes
0
Antibodies, Neutralizing
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
100954Subventions
Organisme : Wellcome Trust
ID : 203268/Z/16/Z
Pays : United Kingdom
Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests L.C.L. and R.S.B. hold patents on norovirus vaccine design and ongoing collaborations with Vaxart, Takeda Vaccines, HilleVax, and BioNTech that are unrelated and do not pose conflicts of interest with this report. R.S.B. is a member of the advisory committee for Vaxart and Invivyd.
Références
J Gen Virol. 2019 Oct;100(10):1393-1406
pubmed: 31483239
Lancet. 2017 Dec 17;388(10063):3027-3035
pubmed: 27839855
Proc Natl Acad Sci U S A. 2021 Mar 16;118(11):
pubmed: 33836574
Infect Genet Evol. 2020 Aug;82:104280
pubmed: 32165242
J Immunol Res. 2022 Jul 29;2022:8287087
pubmed: 35935586
mBio. 2022 Oct 26;13(5):e0186122
pubmed: 36102514
Brain Dev. 2018 Sep;40(8):699-706
pubmed: 29681427
Lancet. 2012 Jun 9;379(9832):2151-61
pubmed: 22579125
J Infect Dis. 2015 Mar 15;211(6):870-8
pubmed: 25210140
J Virol. 2007 Sep;81(18):9932-41
pubmed: 17609280
N Engl J Med. 2013 Mar 21;368(12):1121-30
pubmed: 23514289
Emerg Infect Dis. 2008 Aug;14(8):1224-31
pubmed: 18680645
Trends Immunol. 2021 Nov;42(11):956-959
pubmed: 34580004
PLoS Pathog. 2012;8(5):e1002705
pubmed: 22615565
Immunity. 2021 Aug 10;54(8):1853-1868.e7
pubmed: 34331873
Infect Genet Evol. 2022 Oct;104:105348
pubmed: 35952938
PLoS Med. 2015 Mar 24;12(3):e1001807
pubmed: 25803642
BMC Infect Dis. 2019 Feb 19;19(1):177
pubmed: 30782126
Sci Transl Med. 2020 Dec 9;12(573):
pubmed: 33298562
Eur J Pediatr. 2013 Jun;172(6):739-46
pubmed: 23361964
mBio. 2022 Oct 31;13(6):e0254622
pubmed: 36314798
Scand J Immunol. 2019 Oct;90(4):e12801
pubmed: 31269273
PLoS Pathog. 2012;8(7):e1002802
pubmed: 22829765
Cell Rep. 2020 Aug 4;32(5):107981
pubmed: 32755575
PLoS Med. 2016 Apr 26;13(4):e1001999
pubmed: 27115709
BMC Infect Dis. 2019 Jan 25;19(1):87
pubmed: 30683063
Pediatr Infect Dis J. 2015 Mar;34(3):229-34
pubmed: 25742072
Vaccine. 2020 Sep 22;38(41):6442-6449
pubmed: 32878708
J Virol. 2011 Jan;85(1):231-42
pubmed: 20980508
PLoS Pathog. 2018 May 2;14(5):e1007024
pubmed: 29718999
J Infect Dis. 2020 Feb 18;221(5):739-743
pubmed: 31613328
Am J Trop Med Hyg. 2019 Jul;101(1):164-179
pubmed: 31115304
PLoS One. 2022 Aug 24;17(8):e0272163
pubmed: 36001626
Science. 2004 Jul 16;305(5682):371-6
pubmed: 15218094
J Infect Dis. 2017 Mar 15;215(6):984-991
pubmed: 28453838
J Gastroenterol Hepatol. 2005 Nov;20(11):1685-90
pubmed: 16246186
Immunohematology. 1996;12(2):51-61
pubmed: 15387741
J Virol. 2013 Mar;87(5):2803-13
pubmed: 23269783
Virol J. 2009 Sep 25;6:150
pubmed: 19781066
Pediatr Infect Dis J. 2014 Nov;33(11):1156-63
pubmed: 24879131
J Med Virol. 2008 Aug;80(8):1468-76
pubmed: 18551613
PLoS One. 2014 May 21;9(5):e98201
pubmed: 24849288
Clin Infect Dis. 2021 Oct 20;73(8):1414-1423
pubmed: 33993272
Cell Host Microbe. 2021 Nov 10;29(11):1634-1648.e5
pubmed: 34610295
Heliyon. 2021 Oct 23;7(10):e08250
pubmed: 34761137
Nat Commun. 2021 Jun 18;12(1):3781
pubmed: 34145263
N Engl J Med. 2022 Nov 3;387(18):1716-1718
pubmed: 36223534
J Virol. 2016 May 27;90(12):5574-85
pubmed: 27030262
J Microbiol Immunol Infect. 2021 Oct;54(5):918-925
pubmed: 33531203
J Virol. 2012 Jan;86(2):873-83
pubmed: 22090098
J Virol. 2014 Jul;88(13):7244-55
pubmed: 24648459
Cell Host Microbe. 2022 Dec 14;30(12):1745-1758.e7
pubmed: 36356586
PLoS One. 2008 Jan 23;3(1):e1485
pubmed: 18213393
J Virol. 2014 Jul;88(13):7256-66
pubmed: 24741081
J Microbiol Immunol Infect. 2021 Oct;54(5):909-917
pubmed: 32943327
Immunity. 2020 Feb 18;52(2):388-403.e12
pubmed: 32023489
Viruses. 2019 Mar 06;11(3):
pubmed: 30845670
J Clin Virol. 2013 Mar;56(3):185-93
pubmed: 23218993
Immunity. 2020 Nov 17;53(5):1078-1094.e7
pubmed: 33010224
Viruses. 2021 Jan 30;13(2):
pubmed: 33573340
Science. 2021 Jun 4;372(6546):1108-1112
pubmed: 33947773
PLoS Pathog. 2015 Aug 12;11(8):e1005110
pubmed: 26267277
Front Public Health. 2022 Jun 17;10:905172
pubmed: 35784210
Cell. 2018 Apr 5;173(2):417-429.e10
pubmed: 29625056
J Med Virol. 2022 Aug;94(8):3840-3846
pubmed: 35441419
J Pediatric Infect Dis Soc. 2013 Mar;2(1):57-60
pubmed: 23687584
J Infect Dis. 2013 Dec 1;208(11):1877-87
pubmed: 23908476
Nat Commun. 2021 Jul 26;12(1):4598
pubmed: 34312390
Pediatrics. 2022 Jan 1;149(1):
pubmed: 34918158
PLoS One. 2014 Feb 13;9(2):e88978
pubmed: 24551201
Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2259-64
pubmed: 24469811
Gastroenterology. 2018 Dec;155(6):1898-1907
pubmed: 30170116
Clin Infect Dis. 2021 Aug 16;73(4):e913-e920
pubmed: 34398953
Curr Protoc Microbiol. 2013 Nov 05;31:15K.1.1-15K.1.45
pubmed: 24510290
J Med Virol. 2016 Nov;88(11):1837-43
pubmed: 27110852
Viruses. 2019 Apr 10;11(4):
pubmed: 30974898
Science. 2016 Nov 11;354(6313):722-726
pubmed: 27846599
Viruses. 2021 Oct 09;13(10):
pubmed: 34696463
J Infect Dis. 2010 Oct 15;202(8):1212-8
pubmed: 20815703
Am J Trop Med Hyg. 2020 Dec;103(6):2429-2437
pubmed: 33124532
PLoS Med. 2008 Feb;5(2):e31
pubmed: 18271619
Hepatology. 2016 Dec;64(6):1922-1933
pubmed: 27641232
Immunity. 2019 Jun 18;50(6):1530-1541.e8
pubmed: 31216462
Virus Evol. 2020 Nov 21;6(2):veaa067
pubmed: 33381305
Viruses. 2022 Jun 14;14(6):
pubmed: 35746763
mSphere. 2018 Feb 7;3(1):
pubmed: 29435493
Pathogens. 2022 Apr 09;11(4):
pubmed: 35456126
J Virol. 2009 Jun;83(11):5363-74
pubmed: 19297483
MMWR Morb Mortal Wkly Rep. 2022 Sep 23;71(38):1222-1224
pubmed: 36136940
Nat Commun. 2022 Aug 8;13(1):4617
pubmed: 35941152
mBio. 2019 Sep 24;10(5):
pubmed: 31551337
Viruses. 2020 Nov 18;12(11):
pubmed: 33217894
J Virol. 2017 Jun 26;91(14):
pubmed: 28468886
Nat Commun. 2015 Sep 29;6:8443
pubmed: 26416571
J Virol. 2019 Feb 19;93(5):
pubmed: 30541855